Cannabis Stocks Have Cratered 93.6% Since 2021 — Is This the Bottom?

A 93.6 Percent Decline in Five Years

Let that number settle in for a moment: 93.6 percent. That is how much the Global Cannabis Stock Index has dropped since its closing high of 92.48 in February 2021. An investor who put $10,000 into a cannabis index fund at the peak would now be looking at roughly $640. By any measure, this is one of the most devastating sector-wide collapses in modern financial history.

The carnage has been relentless. During the five-year period through early 2026, the index — which currently counts 27 member companies — plunged 85.2 percent. The industry enjoyed a brief rally in Q3 2025, surging 53 percent on optimism around Trump's executive order on rescheduling, but gave back much of those gains with a 14.2 percent Q4 decline. For the full year of 2025, the index dropped 4.2 percent. In 2026, it has been essentially flat.

The question that every cannabis investor, entrepreneur, and industry observer is asking is straightforward: is this the bottom, or is there further to fall?

How We Got Here

Understanding the current state of cannabis equities requires understanding the mania that preceded the crash. The 2020-2021 cannabis stock rally was fueled by a perfect storm of factors that created wildly inflated expectations.

Democratic control of the White House, Senate, and House after the 2020 elections created widespread belief that federal legalization was imminent. Retail investors, empowered by zero-commission trading apps and stimulus checks, poured money into cannabis stocks as part of the broader meme-stock phenomenon. Canadian cannabis companies, many of which were already publicly listed, saw their valuations soar on projections of massive U.S. market entry.

The fundamentals never supported those valuations. Most publicly traded cannabis companies were burning cash, operating in fragmented state-by-state markets, and years away from profitability. When it became clear that federal legalization would not happen quickly — the SAFE Banking Act stalled, comprehensive reform bills died in committee, and the Biden administration showed little appetite for cannabis policy change — the air came out of the bubble spectacularly.

The selloff accelerated through 2022, 2023, and 2024 as cannabis companies contended with oversupply, price compression, regulatory burden, and a capital market that had almost completely closed to the sector. Companies that had raised hundreds of millions of dollars during the boom were forced into painful restructuring, layoffs, and in some cases, bankruptcy.

The Case for a Bottom

Despite the devastation, several factors suggest that cannabis equities may be approaching — or have already reached — a long-term floor.

Valuations Are at Rock Bottom

The most basic argument for a bottom is mathematical. When an index loses 93.6 percent of its value, the remaining downside is mechanically limited. Many cannabis companies are now trading at or below their net asset values, meaning investors are paying less for the stock than the company's physical assets — cultivation facilities, retail locations, real estate — are worth. In distressed industries, these depressed valuations often precede recoveries as value investors and acquirers step in.

Rescheduling Changes the Tax Math

Trump's December 2025 executive order directing the reclassification of marijuana from Schedule I to Schedule III promises potentially transformative tax relief. Under the current 280E provision of the Internal Revenue Code, cannabis businesses cannot deduct ordinary business expenses, resulting in effective tax rates of 70 percent or more. Rescheduling to Schedule III would eliminate the 280E burden, allowing cannabis companies to deduct payroll, rent, marketing, and interest like any other business.

The collective tax savings for the industry are estimated at $2.3 billion annually. For publicly traded companies, this would flow directly to the bottom line, potentially transforming money-losing operations into profitable ones overnight. While the rescheduling process is not yet complete, the direction of travel is clear, and investors are beginning to price in at least partial tax relief.

Balance Sheets Have Improved

The brutal shakeout of the past four years has forced surviving cannabis companies to dramatically improve their financial discipline. Many have reduced headcounts, closed unprofitable operations, renegotiated leases, and focused on positive cash flow rather than growth at all costs. The companies that remain publicly traded in 2026 are, on average, leaner and more operationally sound than they were at the 2021 peak.

Institutional Interest Is Returning

According to global market analyst Lale Akoner at eToro, cannabis equities may be nearing a long-awaited inflection point, with regulatory momentum, improving balance sheets, and reset valuations drawing investor interest back. Several institutional investors who exited the sector during the downturn have quietly re-established positions at current depressed prices.

The Case Against a Bottom

For every argument that cannabis stocks have bottomed, there is a credible counterargument.

Federal Legalization Remains Uncertain

Despite the rescheduling executive order, federal cannabis legalization is not guaranteed. Rescheduling from Schedule I to Schedule III is a significant step, but it does not legalize cannabis or create a federal regulatory framework for commercial sale. The actual implementation of rescheduling — including the regulatory details that will determine its practical impact on the industry — remains uncertain and could take years to finalize.

If the rescheduling process stalls, is challenged in court, or is reversed by a future administration, the modest optimism currently embedded in cannabis stock prices could evaporate quickly.

The Industry Is Still Structurally Challenged

Cannabis remains a state-by-state patchwork with no interstate commerce, no access to traditional banking, and no ability to list on major stock exchanges (illustrated by Weedmaps' voluntary Nasdaq delisting on April 7, 2026, citing compliance burdens and constraints). These structural barriers limit the industry's ability to achieve the scale, efficiency, and capital access that would justify higher valuations.

The illicit market continues to capture a substantial share of consumer spending in key states, and regulatory compliance costs remain burdensome. These factors constrain profitability even for well-managed operators.

Legal Cannabis Sales Growth Is Slowing

While legal cannabis sales are projected to reach approximately $47 billion in 2026, the growth rate has decelerated significantly from the explosive pace of 2019 through 2022. No new states are expected to launch adult-use sales in 2026, and the pipeline of future legalization candidates has thinned, with efforts in Hawaii, New Hampshire, Wisconsin, and Florida all stalling or failing.

Slower revenue growth limits the upside case for cannabis equities, particularly for companies valued on future growth potential rather than current profitability.

What Should Investors Do?

For investors considering cannabis stocks in April 2026, the key question is not whether the sector has bottomed but whether the risk-reward profile has become attractive enough to justify a position. Here are the considerations that matter most.

Time horizon is everything. Cannabis stocks are not a short-term trade. Investors who need liquidity in the next 12 to 24 months should stay away. The sector's recovery — if it comes — will be measured in years, not months. The catalysts that could drive a sustained rally (rescheduling completion, SAFE Banking passage, new state launches) all operate on timelines of one to three years or more.

Focus on operators with positive cash flow. In a depressed market, cash flow is king. Companies generating positive operating cash flow have the staying power to survive continued uncertainty and emerge stronger. Companies still burning cash are at risk of dilutive fundraising or, worse, insolvency.

Diversify within the sector. The 27 companies in the Global Cannabis Stock Index represent a range of business models, geographies, and risk profiles. Multi-state operators (MSOs) with strong retail networks offer different risk-reward characteristics than pure-play cultivators or technology companies. A diversified approach reduces the impact of any single company's failure.

Consider the opportunity cost. A 93.6 percent decline does not guarantee a recovery. Some sectors experience permanent value destruction when fundamental conditions change. While the cannabis industry's long-term trajectory appears positive, the path from here to sustained profitability for public companies is neither certain nor straight.

The Verdict

Is this the bottom? Probably close, but "close" in a sector as volatile as cannabis could still mean months or years of sideways trading before a meaningful recovery materializes. The reset valuations, improving fundamentals, and pending regulatory catalysts create a plausible case for accumulation at current prices — but only for investors with long time horizons, strong stomachs, and a clear understanding that cannabis investing in 2026 remains a high-risk proposition.

The 93.6 percent decline has destroyed wealth, ended careers, and shattered the industry's reputation with mainstream investors. Rebuilding that trust will require something the cannabis sector has always struggled to deliver: patience, discipline, and results that match the promise.